Literature DB >> 16698269

Ligands with a 3,3-diphenylpentane skeleton for nuclear vitamin D and androgen receptors: Dual activities and metabolic activation.

Shinnosuke Hosoda1, Aya Tanatani, Ken-Ichi Wakabayashi, Makoto Makishima, Keisuke Imai, Hiroyuki Miyachi, Kazuo Nagasawa, Yuichi Hashimoto.   

Abstract

Ligands possessing dual vitamin D(3) (VD(3))-agonistic and androgen-antagonistic activities with various activity spectra were prepared based on a substituted 3,3-diphenylpentane (DPP) skeleton. Among the compounds, (R,S)-DPP-1023 [(R,S)-7b] and (S,S)-DPP-0123 [(S,S)-7c] showed the most potent vitamin D(3)-agonistic activity [with potency comparable to that of 1alpha,25-dihydroxyvitamin D(3) (1,25-VD(3))] and nuclear androgen receptor (AR)-binding activity (with higher affinity than that of hydroxyflutamide), respectively. Metabolic activation (reduction of the carbonyl group) of pivaloyl analogs [DPP-1113 (3a), DPP-1013 (3b), DPP-0113 (3c), and DPP-0013 (3d)] in HL-60 cells was found to be necessary for binding to nuclear vitamin D(3) receptor (VDR).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16698269     DOI: 10.1016/j.bmc.2006.04.039

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Recombinant Expression, Isotope Labeling and Purification of the Vitamin D Receptor Binding Peptide.

Authors:  Young Kee Chae; Kiran Singarapu; W Milo Westler; John L Markley
Journal:  Bull Korean Chem Soc       Date:  2011

2.  Computer-aided de novo ligand design and docking/molecular dynamics study of vitamin D receptor agonists.

Authors:  Xiu-Long Shen; Midori Takimoto-Kamimura; Jing Wei; Qing-Zhi Gao
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

3.  Efficient Lead Finding, Activity Enhancement and Preliminary Selectivity Control of Nuclear Receptor Ligands Bearing a Phenanthridinone Skeleton.

Authors:  Yuko Nishiyama; Shinya Fujii; Makoto Makishima; Yuichi Hashimoto; Minoru Ishikawa
Journal:  Int J Mol Sci       Date:  2018-07-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.